TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates
Gossamer Bio, Inc. GOSS
$10.79
▲ +1.36%
(+$0.15)
🔥 High Short Interest
🎈 Low Float
🎢 High Beta
Open
$10.59
Prev Close
$10.65
Day Range
$10.42 – $11.55
52W Range
$8.29 – $309.60
Market Cap
$65.05M
Beta
2.28
EPS (TTM)
$-28.33
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-02-08 |
| Shares Out. | 6,120,000 |
| Website | gossamerbio.com/ ↗ |
| Phone | 13026365400 |
| Employees | 162 |
| Revenue | $9.2M |
| Gross Profit | $9.2M |
| Net Income | $16.9M |
| Free Cash Flow | -$162.6M |
| Total Assets | $76.9M |
| Total Liabilities | $170.9M |
| Equity | -$94.0M |
About Gossamer Bio, Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Gossamer Bio, Inc. is a publicly traded company under the ticker symbol GOSS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-11-01)